Skip to main content

Generic Brovana Availability

Last updated on Jul 6, 2022.

Brovana is a brand name of arformoterol, approved by the FDA in the following formulation(s):

BROVANA (arformoterol tartrate - solution;inhalation)

  • Manufacturer: SUNOVION
    Approval date: October 6, 2006
    Strength(s): EQ 0.015MG BASE/2ML [RLD] [AN]

Has a generic version of Brovana been approved?

Yes. The following products are equivalent to Brovana:

arformoterol tartrate solution;inhalation

  • Manufacturer: ALEMBIC PHARMS LTD
    Approval date: May 10, 2022
    Strength(s): EQ 0.015MG BASE/2ML [AN]
  • Manufacturer: CIPLA
    Approval date: June 22, 2021
    Strength(s): EQ 0.015MG BASE/2ML [AN]
  • Manufacturer: LUPIN
    Approval date: February 7, 2022
    Strength(s): EQ 0.015MG BASE/2ML [AN]
  • Manufacturer: SUN PHARM
    Approval date: May 26, 2022
    Strength(s): EQ 0.015MG BASE/2ML [AN]
  • Manufacturer: TAP
    Approval date: June 22, 2021
    Strength(s): EQ 0.015MG BASE/2ML [AN]
  • Manufacturer: TEVA PHARMS USA
    Approval date: November 9, 2021
    Strength(s): EQ 0.015MG BASE/2ML [AN]
  • Manufacturer: VISTAPHARM
    Approval date: March 2, 2022
    Strength(s): EQ 0.015MG BASE/2ML [AN]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Brovana. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AN Solutions and powders for aerosolization. Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in any of several delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded AN. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are coded BN, unless they have met an appropriate bioequivalence standard. Solutions or suspensions in a specific delivery system will be coded AN if the bioequivalence standard is based upon in vitro methodology, if bioequivalence needs to be demonstrated by in vivo methodology then the drug products will be coded AB.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.